Paul Casanova-Romero
Endocrinology, Diabetes & Metabolism · Port St Lucie, FLNPI 1316963168
Payments from drug & device makers
Across 262 payments — averaging $53.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$4K
- Novo Nordisk$1K
- Tosoh Bioscience, Inc.$1K
- Pfizer$898
- Sanofi-aventis U.S. LLC$877
- Medtronic$742
- plus $5K from 33 others
What the payments were for
- Consulting fees$8806%
- Speaking & faculty fees$3,56526%
- Travel & lodging$3422%
- Food & beverage$7,86657%
- Education$1021%
- Gifts$1,1378%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 5 | $3,605 |
| Novo Nordisk | 61 | $1,275 |
| Tosoh Bioscience, Inc. | 2 | $1,078 |
| Pfizer | 2 | $898 |
| Sanofi-aventis U.S. LLC | 25 | $877 |
| Medtronic(2 entities) | 11 | $742 |
| Lilly USA, LLC | 14 | $558 |
| AstraZeneca | 18 | $544 |
| Insulet Corporation | 11 | $464 |
| Amgen(2 entities) | 5 | $442 |
| Boehringer Ingelheim | 10 | $365 |
| Amarin Pharma, Inc. | 13 | $338 |
| Abbott | 7 | $289 |
| Bayer | 5 | $289 |
| Valeritas, Inc. | 9 | $262 |
| Dexcom, Inc. | 4 | $254 |
| Ascendis Pharma Endocrinology Inc | 4 | $163 |
| BETA Bionics, Inc. | 1 | $149 |
| Mannkind Corporation | 5 | $130 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Merck | 9 | $123 |
| Johnson & Johnson | 5 | $123 |
| Tandem Diabetes Care, Inc. | 2 | $120 |
| Corcept Therapeutics | 5 | $100 |
| Exelixis Inc. | 1 | $87 |
| Xeris Pharmaceuticals, Inc. | 4 | $79 |
| Antares Pharma, Inc. | 4 | $62 |
| AbbVie | 4 | $58 |
| Amneal Pharmaceuticals LLC | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Roche Diabetes Care, Inc. | 1 | $36 |
| Quidel Corporation | 1 | $32 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| Vivus LLC | 1 | $22 |
| IBSA Pharma Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Nalpropion Pharmaceuticals LLC | 1 | $16 |
| Senseonics, Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- 25-OH Vitamin D ST AIA-Pack$2,156
- SOMAVERT$880
- TU, AIA-PACK Calibrator Set$539
- TU, ST, AIA-PACK$539
- JARDIANCE$488
- Ozempic$466
- iLet Bionic Pancreas$448
- Omnipod$346
- MINIMED 780G$262
- TZIELD$253
- EVENITY$241
- FARXIGA$238
- Minimed 670G System$230
- Kerendia$222
- FREESTYLE LIBRE 3$187
- DEXCOM G7 GSS (161)$150
- DEXCOM STELO GLUCOSE BIOSENSOR$150
- iLet Insulin Infusion Kit Inset$149
- iLet Insulin Infusion Kit Contact Detach$149
- TEPEZZA$125
How this compares
$13,893 in reported general payments places this provider in the 70th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 411 | $536,032 |
| OzempicSemaglutide | 277 | $468,368 |
| MounjaroTirzepatide | 310 | $444,658 |
| TrulicityDulaglutide | 230 | $356,297 |
| FarxigaDapagliflozin Propanediol | 185 | $202,500 |
| JanuviaSitagliptin Phosphate | 156 | $196,029 |
| Tresiba Flextouch U-100Insulin Degludec | 225 | $187,975 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 110 | $172,210 |
| Tresiba Flextouch U-200Insulin Degludec | 73 | $166,651 |
| TradjentaLinagliptin | 113 | $105,699 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 396 | $79,270 |
| Humalog Kwikpen U-100Insulin Lispro | 164 | $65,878 |
| Repatha SureclickEvolocumab | 64 | $61,068 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $58,223 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $53,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $558 | $815,473582 claims |
| Boehringer IngelheimJardiance, Tradjenta | $365 | $641,730524 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,275 | $524,579339 claims |
| MerckJanuvia, Janumet | $123 | $221,647179 claims |
| AstraZenecaFarxiga | $544 | $202,500185 claims |
| BayerKerendia | $289 | $29,49417 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $52 | $21,5891,274 claims |
| AbbVieSynthroid | $58 | $20,303231 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $877 | $17,91811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Port St Lucie
- Ahmet ErginPort St Lucie$527K
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.